Patents Assigned to A.P. Pharma
-
Patent number: 11903951Abstract: Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.Type: GrantFiled: June 2, 2017Date of Patent: February 20, 2024Assignee: M et P Pharma AGInventor: Claudia Mattern
-
Patent number: 11723911Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: GrantFiled: January 25, 2021Date of Patent: August 15, 2023Assignee: M ET P PHARMA AGInventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
-
Publication number: 20220062165Abstract: This invention relates to methods of increasing activity of the neurotransmitter acetylcholine in specific brain regions to treat diseases or disorders associated with reduced acetylcholine activity. In particular, the methods relate to intranasal administration of pregnenolone in only one nostril increasing acetylcholine activity only in the amygdala corresponding to this nostril, thus, providing ipsilateral increase of acetylcholine activity.Type: ApplicationFiled: April 16, 2019Publication date: March 3, 2022Applicant: M et P Pharma AGInventor: Claudia Mattern
-
Publication number: 20210283143Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: ApplicationFiled: January 25, 2021Publication date: September 16, 2021Applicant: M ET P PHARMA AGInventors: Claudia MATTERN, Elisabeth TRAIFFORT, Michael SCHUMACHER
-
Patent number: 10898495Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: GrantFiled: March 11, 2020Date of Patent: January 26, 2021Assignee: M ET P PHARMA AGInventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
-
Patent number: 10729646Abstract: Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprises an agent that binds to one or more air pollutants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described are nasal compositions comprising an agent comprising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. The compositions also may comprise other agents, such as an immunosuppressant. Also described are methods of making and using the compositions.Type: GrantFiled: June 22, 2018Date of Patent: August 4, 2020Assignee: M ET P PHARMA AGInventor: Claudia Mattern
-
Publication number: 20200206244Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: ApplicationFiled: March 11, 2020Publication date: July 2, 2020Applicant: M ET P PHARMA AGInventors: Claudia MATTERN, Elisabeth TRAIFFORT, Michael SCHUMACHER
-
Patent number: 10596181Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: GrantFiled: July 9, 2019Date of Patent: March 24, 2020Assignee: M ET P PHARMA AGInventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
-
Publication number: 20190328750Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: ApplicationFiled: July 9, 2019Publication date: October 31, 2019Applicant: MET P PHARMA AGInventors: Claudia MATTERN, Elisabeth TRAIFFORT, Michael SCHUMACHER
-
Publication number: 20180296472Abstract: Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprises an agent that binds to one or more air pollutants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described are nasal compositions comprising an agent comprising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. The compositions also may comprise other agents, such as an immunosuppressant. Also described are methods of making and using the compositions.Type: ApplicationFiled: June 22, 2018Publication date: October 18, 2018Applicant: M et P Pharma AGInventor: Claudia MATTERN
-
Publication number: 20180200203Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.Type: ApplicationFiled: September 26, 2017Publication date: July 19, 2018Applicant: M ET P PHARMA AGInventor: Claudia MATTERN
-
Patent number: 9962394Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained scrum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: GrantFiled: January 11, 2017Date of Patent: May 8, 2018Assignee: M ET P PHARMA AGInventor: Claudia Mattern
-
Publication number: 20180008615Abstract: Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.Type: ApplicationFiled: June 2, 2017Publication date: January 11, 2018Applicant: M et P Pharma AGInventor: Claudia Mattern
-
Patent number: 9801834Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.Type: GrantFiled: October 13, 2015Date of Patent: October 31, 2017Assignee: M ET P PHARMA AGInventor: Claudia Mattern
-
Publication number: 20140142131Abstract: Long acting injectable analgesic formulations and methods for providing long lasting pain relief in animals are disclosed.Type: ApplicationFiled: November 8, 2013Publication date: May 22, 2014Applicant: A.P. PHARMA, INC.Inventors: Peter Hanson, Joseph K. Rosentel, John Barr
-
Publication number: 20140107226Abstract: Disclosed herein are methods of enhancing the stability of a sustained pharmaceutical composition comprising an active agent and a polymer and methods of preparing such pharmaceutical compositions with enhanced stability.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: A.P. PHARMA, INC.Inventors: Devang T. Shah, John Barr
-
Publication number: 20130178538Abstract: Long acting injectable analgesic formulations and methods for providing long lasting pain relief in animals are disclosed.Type: ApplicationFiled: June 29, 2012Publication date: July 11, 2013Applicants: MERIAL LIMITED, A.P. PHARMAInventors: Peter Hanson, Joseph K. Rosentel, JR., John Barr
-
Publication number: 20120283253Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: ApplicationFiled: July 18, 2012Publication date: November 8, 2012Applicant: A.P. PHARMA, INC.Inventors: Steven Y. NG, Hui-Rong Shen, Jorge Heller
-
Patent number: 8252304Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: September 22, 2009Date of Patent: August 28, 2012Assignee: A. P. Pharma, Inc.Inventors: Steven Y. Ng, Hui Rong Shen, Jorge Heller
-
Patent number: D679805Type: GrantFiled: February 22, 2011Date of Patent: April 9, 2013Assignee: M et P Pharma AGInventor: Alexander Keller